Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)
Close on Nov 18, 2026Market cap $441.37MP/E –Yield –
Ovid Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ovid Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$54.77M. For fiscal 2025 it was -$38.33M. The highest annual figure on record is $118.61M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.33M | – |
| FY2024 | Dec 31, 2024 | -$55.96M | – |
| FY2023 | Dec 31, 2023 | -$45.78M | – |
| FY2022 | Dec 31, 2022 | -$55.23M | -146.6% |
| FY2021 | Dec 31, 2021 | $118.61M | – |
| FY2020 | Dec 31, 2020 | -$51.58M | – |
| FY2019 | Dec 31, 2019 | -$51.09M | – |
| FY2018 | Dec 31, 2018 | -$45.56M | – |
| FY2017 | Dec 31, 2017 | -$31.47M | – |
| FY2016 | Dec 31, 2016 | -$17.80M | – |
| FY2015 | Dec 31, 2015 | -$5.49M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.69M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.09M | -112.5% |
| Q4 FY2021 | Dec 31, 2021 | -$12.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.87M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.42M | – |
| Q1 FY2021 | Mar 31, 2021 | $160.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.47M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.49M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.87M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.05M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.93M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.01M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.32M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.99M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.16M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.71M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.64M | – |
See a number that looks wrong?